GASTROINTESTINAL AND ABDOMINAL RADIOLOGY / ORIGINAL PAPER
Figure from article: Fibrosis-4 and Fibrosis-5...
 
KEYWORDS
TOPICS
ABSTRACT
Purpose:
Hepatic fibrosis can be predicted using fibrosis-4 (FIB-4) and fibrosis-5 (FIB-5) scores. Functional liver imaging score (FLIS) provides valuable information regarding hepatic function. We aimed to assess whether easily obtained blood parameters (FIB-4 and FIB-5) may be used to discriminate preserved and impaired hepatic function based on FLIS.

Material and methods:
Patients who underwent dynamic upper abdominal MRI with gadoxetic acid were retrospectively reviewed (n = 101, mean age 61.0 ± 11.3 years). FLIS values were categorized as FLIS < 4 (impaired hepatic function) and FLIS ≥ 4 (preserved hepatic function). The discriminative potential of FIB-4 and FIB-5 was assessed by plotting ROC curves.

Results:
While FIB-4 was significantly higher, FIB-5 was significantly lower in patients with FLIS < 4. They had significant discriminative value in distinguishing patients with preserved and impaired hepatic function (area under the ROC curves 0.794 for FIB-4 and 0.748 for FIB-5, p-values < 0.001). Comparison of the area under the 2 ROC curves revealed that FIB-4 and FIB-5 had similar discriminative values (p = 0.405). For FIB-4, a cut-off value of 4.2 had a sensitivity of 88.9%, specificity of 66.3%, PPV of 20.5%, and NPV of 98.4%, meaning that FIB-4 values of < 4.2 are valuable in ruling out FLIS < 4 (poor hepatic function). For FIB-5, a cut-off value of 36.2 had a sensitivity of 88.9%, specificity of 60.9%, PPV of 18.2%, and NPV of 98.2%, meaning that FIB-5 values of > 36.2 are valuable in ruling out FLIS < 4.

Conclusions:
FIB-4 and FIB-5 are valuable in discriminating preserved and impaired hepatic function based on FLIS scoring with similar diagnostic performance.
REFERENCES (13)
1.
European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689.
 
2.
Attallah AM, Shiha GE, Omran MM, Zalata KR. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res 2006; 34: 163-169.
 
3.
Metwally K, Elsabaawy M, Abdel-Samiee M, Morad W, Ehsan N, Abdelsameea E. FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clin Exp Hepatol 2020; 6: 335-338.
 
4.
Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, et al. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017; 11: 286-291.
 
5.
Ichikiwa S, Goshima S. Gadoxetic acid-enhanced liver MRI: everything you need to know. Invest Radiol 2024; 59: 53-68.
 
6.
Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y,et al. Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 2020; 294: 98-107.
 
7.
Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, et al. Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using quali­tative and quantitative parameters. Invest Radiol 2016; 51: 728-734.
 
8.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
 
9.
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics (Basel) 2021; 11: 98. DOI: 10.3390/diagnostics11010098.
 
10.
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161: 1657-1669.
 
11.
Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. Consensus report from the 9(th) International. Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021; 31: 5615-5628.
 
12.
Poetter-Lang S, Bastati N, Messner A, Kristic A, Herold A, Hodge JC, et al. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 2020; 45: 3532-3544.
 
13.
Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Sto­yanova DP, et al. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019; 29: 6600-6610.
 
Journals System - logo
Scroll to top